Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 213

Similar articles for PubMed (Select 21670545)

1.

Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease.

Abe M, Maruyama N, Yoshida Y, Ito M, Okada K, Soma M.

Endocr J. 2011;58(8):663-74. Epub 2011 Jun 14.

2.

Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy.

Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.

J Atheroscler Thromb. 2011;18(11):1018-28. Epub 2011 Sep 15.

3.

Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease.

Sawara Y, Takei T, Uchida K, Ogawa T, Yoshida T, Tsuchiya K, Nitta K.

Intern Med. 2008;47(17):1505-10. Epub 2008 Sep 1.

4.
6.

Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.

Mazza F, Stefanutti C, Di Giacomo S, Vivenzio A, Fraone N, Mazzarella B, Bucci A.

Am J Cardiovasc Drugs. 2008;8(4):265-70.

PMID:
18690760
7.

Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.

Yamazaki D, Ishida M, Watanabe H, Nobori K, Oguma Y, Terata Y, Koyama T, Iino K, Kosaka T, Ito H.

Lipids Health Dis. 2013 Feb 4;12:9. doi: 10.1186/1476-511X-12-9.

8.

The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.

Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M; DISCOVERY PENTA investigators.

Curr Med Res Opin. 2005 Aug;21(8):1307-15.

PMID:
16083541
9.
10.
11.

A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.

Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, Elisaf MS.

Clin Ther. 2007 Jul;29(7):1403-14.

PMID:
17825691
12.

Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?

Milionis HJ, Gazi IF, Filippatos TD, Tzovaras V, Chasiotis G, Goudevenos J, Seferiadis K, Elisaf MS.

Angiology. 2005 Sep-Oct;56(5):585-92.

PMID:
16193198
13.
14.
15.

Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease.

Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF.

Am J Cardiol. 2005 Nov 1;96(9):1290-2. Epub 2005 Sep 8.

PMID:
16253600
16.

Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.

Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS.

Am Heart J. 2006 May;151(5):975.e1-9.

PMID:
16644314
17.

Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.

Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, Cressman M.

Am Heart J. 2004 Jul;148(1):e4.

PMID:
15215813
18.

Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.

Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, McDonough KL, Willey VJ.

Pharmacotherapy. 2006 Apr;26(4):469-78.

PMID:
16553504
19.

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.

Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW; Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.

Clin Ther. 2004 Sep;26(9):1388-99. Erratum in: Clin Ther. 2005 Jan;27(1):142.

PMID:
15531001
20.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk